Does Cosentyx Affect Vaccine Response?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, impairs immune responses to vaccines. Clinical data show it reduces antibody production, particularly for non-live vaccines like influenza and pneumococcal. In trials, patients on Cosentyx had lower seroprotection rates—e.g., 28-43% for influenza strains vs. 50-70% in placebo groups—indicating weaker protection.1
Which Vaccines Are Impacted Most?
- Inactivated/non-live vaccines: Moderate reduction in efficacy. A phase 3 trial found 45% seroconversion to pneumococcal vaccine (vs. 67% placebo), persisting up to 52 weeks.1
- Live vaccines: Contraindicated due to immunosuppression risk; Cosentyx labeling advises avoidance.2
- COVID-19 mRNA vaccines: Real-world studies report 20-30% lower antibody titers in IL-17 inhibitor users, with faster waning immunity.3
| Vaccine Type | Seroprotection Rate on Cosentyx | Placebo/Control Rate |
|--------------|---------------------------------|----------------------|
| Influenza | 28-43% | 50-70% |
| Pneumococcal| ~45% | ~67% |
| Tetanus | 70-80% (less affected) | 90-95% |
How Long Does the Effect Last?
Suppression starts within weeks of dosing and lasts through treatment (every 4 weeks). Post-discontinuation, immune recovery takes 3-6 months, based on IL-17 pathway normalization.1 No data on boosters fully restoring levels mid-treatment.
Recommendations for Patients on Cosentyx
Novartis guidelines: Vaccinate before starting therapy. Use higher-dose or adjuvanted vaccines if possible; monitor titers annually. Avoid live vaccines like MMR, varicella, or yellow fever.2 Rheumatologists often prioritize pneumococcal, shingles (recombinant version), and flu shots pre-treatment.
Risks of Reduced Protection
Higher infection rates in trials (e.g., 1.5-2x upper respiratory infections), though not directly tied to vaccine failure. Case reports link IL-17 inhibitors to severe COVID-19 breakthroughs despite vaccination.3 No increased mortality signal, but vulnerable patients (elderly, comorbidities) face breakthrough risks.
Comparisons to Other Biologics
Cosentyx impairs less than TNF inhibitors (e.g., Humira: 10-20% pneumococcal response) but more than JAK inhibitors (e.g., Xeljanz: near-normal flu response).4 IL-23 inhibitors like Tremfya show milder effects.